Relapsed or Refractory Acute Myeloid Leukemia (AML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Acute myeloid leukemia (AML) is characterized by the uncontrolled growth of undifferentiated myeloid stem cells, accumulating immature myeloblasts. The standard approach to induce remission in AML has been a chemotherapy regimen combining cytarabine and anthracycline (commonly called “7+3″) for thirty years. However, relapse and refractory disease persist despite its long-standing use, with a median overall survival of under 6 months. Several factors have been linked to worse outcomes, including age exceeding 65 years, unfavorable cytogenetics, and a first complete remission lasting less than 12 months. The treatment of relapsed or refractory AML presents low remission rates following initial salvage therapy, and these rates decline further with subsequent treatment attempts. The sole curative option for relapsed or refractory AML patients is a hematopoietic stem cell transplant, but its high mortality risk renders it unsuitable for many patients.

Thelansis’s “Relapsed or Refractory Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Relapsed or Refractory Acute Myeloid Leukemia (AML) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Acute Myeloid Leukemia (AML) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Relapsed or Refractory Acute Myeloid Leukemia (AML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033